Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

Haemophilia A: full-pipeline trial registry

3 of 9 indexed Haemophilia A trials are currently recruiting.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Haemophilia A: 9 US clinical trials tracked, 3 recruiting.

Haemophilia A is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 8 of these trials.

Enrollment posture brief

Registry condition haemophilia-a

OPEN 3 | RECR 33% | LATE 4 | EARLY 3 | RANK #1916 | SPON 8

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Haemophilia A (this)33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Haemophilia A

Haemophilia A lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Haemophilia A on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Haemophilia A is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Haemophilia A research.

    Novo Nordisk A/S accounts for 8 of 9 trials (88.9%). 2 distinct sponsors appear on at least one study for this condition label.

  3. Typical Haemophilia A enrolment sits around 186 participants.

    Median target enrolment is 186 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.

  4. Haemophilia A research is mostly interventional.

    7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 34

Open and recent trials

9 total, page 1 of 1

RECRUITING 200 participants

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

Octapharma

NCT03695978

RECRUITING Phase 1 80 participants

A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People

Novo Nordisk A/S

NCT07238816

RECRUITING Phase 1 20 participants

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

Novo Nordisk A/S

NCT07220564

ACTIVE NOT RECRUITING Phase 3 451 participants

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)

Novo Nordisk A/S

NCT05685238

COMPLETED 563 participants

A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia

Novo Nordisk A/S

NCT03660774

COMPLETED Phase 3 214 participants

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

Novo Nordisk A/S

NCT00984126

COMPLETED Phase 3 186 participants

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

Novo Nordisk A/S

NCT01480180

COMPLETED Phase 3 65 participants

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

Novo Nordisk A/S

NCT01138501

COMPLETED Phase 1 24 participants

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Novo Nordisk A/S

NCT02490787

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 3 4

Top Sponsors

Novo Nordisk A/S 8 trials
Octapharma 1 trials

Named interventions

Most-linked intervention names on Haemophilia A records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

turoctocog alfa Drug
2 trials
NNC0442-0344 A Drug
2 trials
turoctocog alfa pegol Drug
1 trials
No treatment given Other
1 trials
Concizumab Drug
1 trials
Mim8 Drug
1 trials
placebo Drug
1 trials

US sites by state

Facility locations filed on Haemophilia A trials. A trial with sites in several states counts in each.

California 7 trials
Iowa 6 trials
Florida 6 trials
Georgia 5 trials
Ohio 4 trials
Michigan 4 trials
Massachusetts 4 trials
Indiana 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Haemophilia A page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Haemophilia A condition card totals 9 registered trials; most-linked intervention turoctocog alfa; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.